PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
PRINCETON, N.J. and SHANGHAI, June 7, 2012 /PRNewswire/ -- PharmaNet/i3 , inVentiv Health's clinical segment, and a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it has been named the recipient of the US Chinese Anti-Cancer Association  (USCACA) Distinguished Partner Award for its support of oncology clinical trials and cancer research in China. USCACA is a non-profit organization that facilitates collaborations among cancer researchers and physicians in the US and China. The award was presented to PharmaNet/i3 at the USCACA's Annual Meeting held at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2, 2012.
"To elevate Chinese clinical research to the leading global level requires close partnership not only among academia, industry sponsors, and regulatory agencies, but also with CROs. CROs like PharmaNet/i3 represent a critical force in implementing and executing high quality clinical research, and can provide unique contributions to facilitate multi-center and multi-disciplinary collaborations," commented Li Yan, MD, PhD, Managing Director of the USCACA and Head of Infectious Disease, Oncology, Respiratory & Immunology Clinical Development, Emerging Markets, Merck.
Wei Zhang, PhD, President of USCACA and Professor and Director, Cancer Genomics Core Laboratory, M.D. Anderson Cancer Center added, "We very much appreciate the PharmaNet/i3 team's strong support of our initiatives in China. It is an exceptional demonstration of social responsibility."
In September 2011, representatives from PharmaNet/i3 conducted a session at the USCACA-Chinese Society for Clinical Oncology (CSCO) joint workshop on early phase oncology clinical trials in China. The session was developed to engage medical professionals and investigators from top c